MONTREAL, CANADA--(Marketwire - Feb. 5, 2008) - Not for distribution to U.S. news wire services or dissemination in the United States. Theratechnologies (TSX:TH) today announced that it has filed a final short form base shelf prospectus and the prospectus supplement thereto with the Canadian provincial securities regulatory authorities in connection with an underwriting agreement entered into with a syndicate of underwriters led by BMO Capital Markets, including Canaccord Capital, National Bank Financial, Desjardins Securities and Jennings Capital. Under such agreement, the underwriters have agreed to buy 3,500,000 common shares from the Company and sell them to the public at a price of $8.50 per share, representing an aggregate issue amount of $29,750,000. The Company has also granted to the underwriters an over-allotment option to purchase an additional 350,000 common shares at the same price ($2,975,000), exercisable by the underwriters for a period of 30 days from closing. If the over-allotment option is exercised in full, the gross proceeds to the Company will total $32,725,000. Closing is expected to occur on or about February 13, 2008 and is subject to customary closing conditions.
